Single peptide Vial strength 20 mg
Livagen20 mg
Explore the format, calculations, and schedules reported for this compound.
Back to peptides
Get to know the compound
Livagen, explained simply
A synthetic tetrapeptide explored in research on enzyme activity and the regulation of gene expression.
Research area
Ageing biology and cellular models
How it works
Experiments describe enzymes that break down enkephalins and chromatin changes in senescent cells.
Why it matters
It illustrates how an in-vitro molecular hypothesis does not automatically become a treatment.
What has been observed
The cited observations mainly involve cells and animal models; no standard human schedule is established.
Effects and points to consider
Adequate clinical data to infer human efficacy, duration or safety are lacking.
01 / Vial strength 20 mg
Reported data
Doses and cycles are presented for information and education only; they are not prescriptions or medical advice.
Reported vial strength and reconstitution
| Vial contents | 20 mg Livagen |
|---|---|
| Final volume | 3 mL |
| Concentration | 6.67 mg/mL |
| One U-100 unit | 66.67 mcg in 0.01 mL |
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (500 mcg) | 7.5 units (0.075 mL) |
| Weeks 3–4 | 1.0 mg (1000 mcg) | 15 units (0.15 mL) |
| Weeks 5–6 | 1.5 mg (1500 mcg) | 22.5 units (0.225 mL) |
| Weeks 7–12 | 2.0 mg (2000 mcg) | 30 units (0.30 mL) |
Supplies needed
View on Amazon
Sterile alcohol swabs
SOURCES
Scientific references
Links reported by the source and selected by type. Their presence does not validate this page’s dosage data.